European Journal of Sustainable Development Research
2025, 9(2), em0283
e-ISSN: 2542-4742
https://www.ejosdr.com/

MODESTUM

Review Article

OPEN ACCESS

Novel mechanism for protein delivery in breast cancer therapy: A public health perspective

Taiwo Temitope Ogunjobi [1*], Ngozi Maryann Nebolisa [2], Rufus Oluwagbemileke Ajayi [3], Morenikeji Ibilola Euba [4], Adnan Musa [5], Abdul-Hanan Saani Inusah [6], Femi Adedayo [7], Ojoisimi Franca Jamgbadi [8], Akinwunmi Rapheal Afuape [9], Adeleye Adegboyega Edema [10], Stephen Ajuluchukwu Echesi [11], Daniel Ebubechi Obasi [12], Sulaimon Olajuwon Abdul [13], Saheed Adegbola Adeyanju [14]

[1] Department of Biochemistry, Faculty of Basic Medical Sciences, Ladoke Akintola University of Technology, Ogbomosho, Oyo State, NIGERIA
[2] Department of Pharmacy, Faculty of Pharceutical Sciences, Nnamdi Azikiwe University, Awka, Anambra State, NIGERIA
[3] Department of Public Health, University of Illinois at Springfield, Springfield, IL, USA
[4] Department of Nutritional Science, University of Calabria, Arcavacata, ITALY
[5] Department of Epidemiology, First Moscow State Medical University, Moscow, RUSSIA
[6] School of Medicine, University for Development Studies, Tamale, GHANA
[7] Department of Computer Science, Imo State University, Owerri, Imo State, NIGERIA
[8] Department of Pharmacy, Faculty of Pharmacy, University of Benin, Benin, Edo State, NIGERIA
[9] Department of Biology, Faculty of College of Science and Technology, North Carolina Agriculture and Technical University, Greensboro, NC, USA
[10] Department of Biochemistry, Faculty of Basic Medical Science, Olabisi Onabanjo University, Ago Iwoye, Ogun State, NIGERIA
[11] Department of Microbiology, Faculty of Biological Sciences, University of Port Harcourt, Port Harcourt, NIGERIA
[12] Department of Medicine and Surgery, University of Ibadan, Ibadan, Oyo State, NIGERIA
[13] Department of Pharmacy, Faculty of Pharmacy, Olabisi Onabanjo University, Ago Iwoye, Ogun State, NIGERIA
[14] Department of Bioinformatics, School of Health and Life Science, Teesside University, Middlesbrough, UK
***Corresponding Author:** ogunjobitaiwo95@gmail.com

Citation: Ogunjobi, T. T., Nebolisa, N. M., Ajayi, O. A., Euba, M. I., Musa, A., Inusah, A.-H. S., Adedayo, F., Jamgbadi, O. F., Afuape, A. R., Edema, A. A., Echesi, S. A., Obasi, D. E., Abdul, S. O., & Adeyanju, S. A. (2025). Novel mechanism for protein delivery in breast cancer therapy: A public health perspective. *European Journal of Sustainable Development Research, 9*(2), em0283. https://doi.org/10.29333/ejosdr/16054

ARTICLE INFO

Received: 10 Jun. 2024

Accepted: 27 Aug. 2024

ABSTRACT

Breast cancer is still a major global public health concern, requiring novel treatment strategies that might enhance results and minimize adverse effects. From the perspective of public health, this review highlights the potential of innovative routes for protein delivery in breast cancer treatment to change therapeutic approaches. We investigate sophisticated protein delivery methods, such as ligand-directed targeting, nanoparticle-based carriers, and bioengineered proteins, and evaluate their efficacy in maximizing medication specificity and reducing toxicity through a methodical review of recent literature. According to our research, the distribution of therapeutic proteins to breast cancer cells is greatly enhanced by these innovative delivery methods, which increases treatment efficacy while lowering systemic exposure and side effects. Specifically, biological barriers have been demonstrated to be achievable by targeted delivery systems, which also target the tumor microenvironment. This allows for the localized release of therapeutic medicines at the tumor site. These developments have significant implications, including the possibility of more individualized and minimally invasive breast cancer therapy choices. These innovative delivery methods can improve patient quality of life and adherence to treatment plans by lessening the adverse effects of conventional chemotherapy, which will improve overall treatment outcomes. Looking forward, it will be crucial to conduct more research and development on protein delivery systems. Future directions ought to concentrate on investigating combination medicines, refining delivery systems for practical usage, and carrying out extensive clinical trials to assess efficacy and safety. This study highlights the role of public health in promoting access to these innovations and enhancing cancer care, underscoring the significance of incorporating novel protein delivery systems into treatment options for breast cancer.

Keywords: breast cancer therapy, protein delivery systems, public health, nanoparticle carriers, targeted treatment, therapeutic innovation

INTRODUCTION

The Global Burden of Breast Cancer

Breast cancer is still the most prevalent disease among women worldwide, and it poses a serious public health issue that cuts across both social and geographic divides. As evidenced by the cancer's increasing prevalence, high death rate, and severe detrimental effects on survivors' quality of life (QoL), breast cancer is becoming more commonplace despite improvements in diagnosis techniques and treatment alternatives. This thorough research explores the complex

global burden of breast cancer and emphasizes the need for coordinated international action to address this illness (Li et al., 2019). Globally, the prevalence of breast cancer has increased noticeably over the last several decades, and it is now the leading cause of cancer-related morbidity and death in women. According to the World Health Organization, there were around 2 million new cases of breast cancer and 685,000 deaths from the disease globally in 2020 alone, showing a worrying upward trend (Lima et al., 2021). The population's expansion and aging, together with the adoption of westernized lifestyles that include dietary modifications, decreased physical activity, and reproductive practices, can all be partially blamed for this increase (Kopp, 2019).

Breast cancer affects people differently around the world, with high- and low-income countries (HICs) and low- and middle-income nations (LMICs) having notably different incidence and prognosis. Despite the fact that HICs have greater incidence rates, LMICs experience disproportionately higher death rates, which are linked to late-stage diagnoses and restricted access to prompt and efficient treatment. These differences highlight how important it is to increase access to cancer care and put in place efficient screening and early detection programs all across the world (Heer et al., 2020). Beyond death, the socioeconomic burden of breast cancer includes the high costs of care and treatment, lost wages, and the psychological and emotional toll that the disease has on patients and their families. The physical side effects of breast cancer therapy, continuous pain, lymphedema, and the psychological repercussions of having a cancer diagnosis are just a few of the long-term impacts that have a substantial impact on survivors' QoL and capacity to reintegrate into society (Coughlin, 2019).

Survival rates have increased as a result of advances in our knowledge of the genetics and treatment of breast cancer, especially in nations with developed healthcare systems and extensive cancer care initiatives. However, a more proactive worldwide approach is required in light of the rising incidence of breast cancer, with a focus on research, prevention, early diagnosis, and fair access to care. Controlling breast cancer must be the top priority in public health plans, which must also integrate efforts from all disciplines and sectors and customize interventions to fit the various needs of communities around the globe (Basu et al., 2020). A coordinated global response is required due to the significant public health problem posed by the global incidence of breast cancer.

Current Challenges in Breast Cancer Treatment and Public Health

This comprehensive review delves into the current obstacles facing breast cancer treatment and public health, highlighting the need for integrated solutions and international cooperation. Despite significant progress in understanding the biology of the disease and developing more effective therapies, treatment and management of breast cancer continue to face a myriad of challenges that span clinical, operational, and socio-economic domains, significantly impacting public health systems worldwide (Ponce-Chazarri et al., 2023). The heterogeneity of breast cancer presents a significant clinical issue in the treatment of the disease, since it might present with different genetic profiles, tumor features, and therapeutic responses in patients.

Due to this variation, treatment must be tailored to each patient individually, requiring careful consideration of several options before deciding on the best course of action. However, especially in nations with LMICs, the use of precision medicine is frequently impeded by gaps in genetic testing, biomarker discovery, and the availability of targeted treatments (Ranganathan et al., 2021). Breast cancer care is also greatly impacted by operational issues, with gaps in treatment access, diagnosis, and screening leading the way. Poorer outcomes result from delays in cancer detection and treatment initiation caused by inadequate healthcare infrastructure, a lack of oncology professionals with the necessary training, and a dearth of sophisticated diagnostic and therapeutic technology in many places. Furthermore, the current healthcare systems are under pressure from the rising demand for cancer care services, which calls for significant investments in workforce training and healthcare capacity expansion (Agaronnik et al., 2022).

Public health initiatives and the treatment of breast cancer are further complicated by socioeconomic issues. The exorbitant cost of cancer treatment creates a significant financial strain on individuals, families, and healthcare systems. This includes costs for surgery, chemotherapy, radiation therapy, and innovative targeted treatments. There are notable differences in treatment access and results as a result of this cost burden being amplified in environments without comprehensive health insurance or other financial support systems (Rainey et al., 2018). Especially in some sociocultural situations, cultural stigma and ideas about cancer might impede efforts to detect the disease early on and to stick to treatment plans. Effective breast cancer prevention techniques, population-based screening programs, and public awareness campaigns are among the public health issues that need to be addressed. Incorporating lifestyle modification initiatives into public health campaigns to address modifiable risk factors such as obesity, physical inactivity, and alcohol consumption is still insufficient. Widespread adoption of evidence-based screening programs is also desperately needed in order to promote early diagnosis and treatment initiation, which greatly raises survival rates (Thomas et al., 2022).

Aim

The goal of this article is to investigate and clarify a unique route for protein delivery in breast cancer therapy, with a focus on how it might enhance patient outcomes and treatment efficacy. This review aims to provide a thorough understanding of how the most recent developments in protein delivery systems, including nanocarriers, bioconjugates, and tailored delivery techniques, may navigate around the limitations of conventional cancer therapy. Our objective is to shed light on the processes via which these systems improve the bioavailability, targeting accuracy, and stability of therapeutic proteins used in the treatment of breast cancer. This review provides a critical examination of developing technologies and synthesizes recent research findings to expand the current understanding of protein delivery in breast cancer therapy. We provide insights into the molecular interactions and pathways involved in these enhanced delivery methods by concentrating

on the unique mechanisms that improve therapeutic efficacy and delivery efficiency. This review also discusses the disadvantages and limitations of the protein delivery techniques currently in use, offering potential improvements and future research avenues to maximize therapeutic results. Our findings have substantial potential benefits for stakeholders. This review offers researchers and physicians important information that help direct the development of more focused and efficient treatments for breast cancer. The development of next-generation therapeutic drugs and delivery systems can benefit from pharmaceutical companies' knowledge of innovative delivery mechanisms. In the end, patients stand to benefit from increased therapeutic efficacy, fewer side effects, and a higher QoL thanks to developments in protein delivery systems. Through its ability to link cutting-edge research to real-world applications, this review highlights the significance of ongoing investigation and advancement in the field of breast cancer therapy.

Knowledge Gap

Although protein delivery systems for breast cancer therapy have advanced, there are still several unanswered questions that prevent these technologies from reaching their full potential. The incomplete knowledge of these innovative delivery systems' long-term safety and effectiveness is one major gap. Comprehensive clinical trials and longitudinal investigations are required to determine whether therapeutic effects are long-lasting and to detect any potential long-term side effects, even though preliminary research indicates promise. To secure regulatory approval and guarantee patient safety, this gap must be filled. The optimization of targeting techniques for protein delivery represents a crucial knowledge gap. Even with the development of numerous targeting ligands and delivery systems, more accurate and effective targeting mechanisms that can distinguish between malignant and healthy tissues with great precision are still required. This involves the development of biomarkers and imaging approaches that can direct and track the real-time administration of therapeutic proteins, improving therapy efficacy and precision. Lastly, a barrier to the broad clinical application of new protein delivery technologies is their reproducibility and scalability. Many novel ideas are still in the experimental phase, and concerns with cost-effectiveness, standardization, and manufacturing must be resolved in order to move from laboratory research to large-scale production and clinical application. To close this gap, university researchers, business associates, and government agencies must work together to create standardized procedures and guarantee that patients can obtain and afford these cutting-edge treatments.

THE PROSPECTS OF NOVEL PROTEIN DELIVERY MECHANISMS

The Prospect of Innovative Protein Delivery to Transform Therapy for Breast Cancer

The treatment of breast cancer has reached a turning point with the development of innovative protein delivery methods, which may drastically change therapy approaches for this common condition. Protein-based treatments have demonstrated great promise in addressing the intricate molecular processes underlying breast cancer, such as enzyme inhibitors, vaccinations, and monoclonal antibodies (mAbs). However, issues with administration, including as stability, specificity, and tumor microenvironment penetration, frequently restrict their effectiveness (Chang et al., 2019). This session examines the emerging topic of new protein delivery systems and how they can transform the way that breast cancer is treated.

Emerging delivery methods including ligand-directed targeting, bioengineered proteins, and nanoparticle-based carriers have posed viable solutions to these problems. For example, therapeutic proteins can be encapsulated in nanoparticle carriers, which shield them from breakdown and enable targeted administration to tumor cells with minimal systemic damage (Tong et al., 2020). By delivering the therapeutic delivery specifically to the tumor location, these nanoparticles can be designed to identify certain cancer cell markers, increasing therapy success and decreasing side effects. The use of therapeutic proteins in conjunction with ligands or antibodies that bind to receptors that are overexpressed on breast cancer cells is known as ligand-directed targeting. Precision targeting not only increases the therapeutic index of protein-based therapies but also opens up new avenues for the use of personalized medicine to the treatment of breast cancer (Mirza & Karim, 2021).

With the creation of altered proteins that have better bloodstream stability, increased tumor penetration, and regulated release mechanisms, bioengineering technologies have also advanced protein delivery systems. The potential exists for these bioengineered proteins to surmount the physiological obstacles that have hitherto hindered the efficient delivery of drugs to solid tumors. These novel protein delivery techniques have significant therapeutic implications for breast cancer. Through the improvement of protein-based medicines' safety, efficacy, and specificity, these technologies have the potential to greatly improve patient outcomes (Delfi et al., 2021). Also, the ability to deliver therapeutic proteins directly to the tumor site creates new opportunities for combination therapies, in which established immunotherapies, radiation therapy, or chemotherapy can be used in concert with protein-based agents to achieve comprehensive cancer control. But there are a lot of obstacles to overcome before these innovative protein delivery methods may be applied in clinical settings (Ghione et al., 2020).

Overview of Advanced Protein Delivery Methods

The field of therapeutic strategies has undergone a considerable revolution with the development of protein delivery systems, especially in oncology. Treatment efficacy and patient outcomes could be greatly improved by being able to precisely and efficiently distribute protein-based therapies. This is particularly relevant to the treatment of breast cancer, as the disease's complexity calls for novel therapeutic strategies (Liu et al., 2019). At the forefront of this transformation are advanced protein delivery techniques including ligand-directed targeting, bioengineered proteins, and nanoparticle-based carriers, which provide new ways to get past conventional obstacles to successful therapy.

Therapeutic protein delivery has shown promise through the use of nanoparticle-based carriers. Proteins can be shielded from immune system clearance and enzymatic breakdown by encasing them in nanoparticles, which lengthens their duration in the bloodstream and increases their stability. These carriers can be designed to have particular characteristics that affect their biodistribution and targeting abilities, like size, charge, and surface changes (Jain et al., 2018). Targeting ligands that bind and recognize particular receptors overexpressed on cancer cells can be added to nanoparticles to functionalize them and enable targeted delivery of the therapeutic delivery straight to the tumor site. Compared to conventional, non-specific delivery methods, this focused strategy represents a substantial leap by maximizing treatment efficacy while minimizing off-target consequences (Seidu et al., 2022).

Utilizing the selectivity of ligand-receptor interactions, ligand-directed targeting is a further cutting-edge strategy that delivers therapeutic proteins to cancerous cells. Using this technique, therapeutic proteins or peptides are conjugated with ligands or antibodies that bind strongly to particular cell surface indicators that are produced by tumor cells (Al-Mansoori et al., 2021). The safety profile of protein-based therapies is improved by this selective targeting, which lowers systemic toxicity and increases therapeutic concentration at the tumor site. The ability of bispecific antibodies to bind to two distinct epitopes at the same time is another example of how ligand-directed targeting can be used to provide precise and efficient drug delivery (Thakur et al., 2018).

ADVANCED PROTEIN DELIVERY METHODS

Ligand-Directed Targeting

Ligand-directed targeting is a significant development in protein therapy and precision medicine, especially as it relates to oncology. This novel strategy reduces systemic toxicity while increasing treatment efficacy by directly delivering therapeutic proteins to cancer cells via the selectivity of ligand-receptor interactions. Because targeted therapy can be used to capitalize on the disease's heterogeneity and the availability of specific molecular targets on cancer cells, this method is very relevant to the treatment of malignancies, especially breast cancer (Bashraheel et al., 2020). Fundamentally, ligand-directed targeting entails the conjugation of therapeutic agents–like proteins, peptides, or nucleic acids–with ligands such as folate or antibodies that are specially designed to recognize and bind to antigens or receptors that are overexpressed on cancer cell surfaces (**Figure 1** and **Table 1**) (Seidi et al., 2018). Therapeutics can be



Figure 1. Illustration of biological ligands for drug-carrying nanoparticle active targeting (Essa et al., 2020)

delivered selectively because of the distinct genetic signatures of tumor cells, which set them apart from normal cells. When these ligand-conjugated medications connect to their specific receptors, they facilitate receptor-mediated endocytosis, which expedites the internalization of the therapeutic administration into the target cells. The synthesis of antibody-drug conjugates (ADCs) is one use of ligand-directed targeting in protein therapy. ADCs couple a monoclonal antibody to a cytotoxic chemical via a stable linker, combining the potent anticancer effect of chemotherapeutic medications with the specificity of antibodies (Zhang et al., 2021).

ADCs target antigens that are overexpressed or specifically expressed on tumor cells, delivering their deadly payload straight to cancer cells. This reduces the adverse effects of chemotherapy and shields healthy tissues from harm. The development of synthetic ligands or peptides that imitate the binding regions of natural ligands is another exciting direction in ligand-directed targeting (Yamaguchi et al., 2021). These artificial ligands provide a flexible platform for the targeted delivery of a variety of therapeutic proteins because they may be engineered to have high affinity and specificity for tumor-associated receptors. Pro-apoptotic proteins, enzymes that interfere with tumor metabolism, and immunomodulatory proteins that boost the immune response against tumors have all been investigated as potential delivery targets using this strategy (Tu et al., 2020). The use of ligand-directed targeting in clinical practice presents a number of difficulties despite its potential. Targeted therapies may be less effective due to the heterogeneity of tumor cells within and between different cancer types; therefore, it is necessary to identify targets that are highly expressed or uniformly expressed (Belfiore et al., 2018). Cancers may downregulate or mutate the target

Table 1. Ligands for actively targeting drug delivery systems in nanoparticles

Type	Ligands (example)	Advantage/disadvantage
Proteins	Antibodies & transferrin	Low stability, high specificity/large size
Polysaccharides	Hyaluronic acid	Can serve as the polymer backbone of live tissue's overexpressed receptors or nanoparticles
peptides	RGD & IL4RPep-1	Simple synthesis, modest size, and peptidase cleavable
Aptamers	AS-1411 & GBI-1	High cost, small size/cleavable by nuclease, and high specificity
Small molecules	Folate & anisamidephenylboronic acid	In normal tissues, targets and small sizes are likewise expressed at extremely little cost.



Figure 2. Diagrammatic illustration of various nanoparticle-based delivery systems: (A) virus-like particle, (B) liposome, (C) immune stimulating complexes, (D) polymeric nanoparticle, (E) inorganic nanoparticle, (F) emulsion, and (G) exosome (Bezbaruah et al., 2022)

receptors, which raise the possibility of resistance to targeted therapy developing. To tackle these obstacles, a thorough grasp of tumor biology is necessary, as is the ongoing discovery of new targets and the creation of combination treatments that can circumvent resistance mechanisms (Swayden et al., 2020).

Also, careful consideration of the conjugates' pharmacokinetics and biodistribution is required to successfully translate ligand-directed targeting strategies into effective treatments. This ensures that the conjugates reach the tumor site in sufficient concentrations to exert their therapeutic effect. Novel approaches to these problems are provided by developments in bioengineering and nanotechnology, which make it possible to create delivery systems that can successfully negotiate the intricate tumor microenvironment (Yoo et al., 2019). Therefore, ligand-directed targeting represents a significant advancement in protein therapy and precision medicine, providing a potent means of delivering medicines to cancer cells in a targeted manner. Ligand-directed targeting has the potential to have a major impact on cancer treatment going forward, ushering in a new era of customized, tailored medicines that maximize efficacy while reducing harm, as research in this field and our understanding of tumor biology increase (Seidi et al., 2018). There is little doubt that further research and improvement of this strategy will advance precision medicine in oncology and enhance the prognosis of cancer patients (Low & Nakamura, 2019).

Nanoparticle-Based Carriers

With the advent of nanoparticle-based carriers as a ground-breaking platform, the field of targeted drug delivery has witnessed a significant breakthrough in the development of therapeutic approaches, particularly in the treatment of cancer (**Figure 2**). By precisely delivering therapeutic agents to illness areas, the creation of nanoparticles for drug delivery overcomes the drawbacks of traditional treatment modalities by utilizing the special qualities of materials at the nanoscale (Yao et al., 2020). A wide range of materials, including lipids, polymers, metals, and biological molecules, can be used to create nanoparticles, which normally have sizes between one and one hundred nanometers. Because of their composition's diversity, nanoparticles can be tailored to meet a variety of therapeutic goals, including targeted delivery to particular tissues or cells, improved drug solubility, and drug protection against degradation (Mirza & Karim, 2021). Encapsulating therapeutic molecules, shielding them from the biological



Figure 3. Therapeutic mAbs' effector mechanisms in cancer treatment (Rodríguez-Nava et al., 2023): (A) blockage of the signaling route, (B) antibody-mediated cytotoxicity on cells, (C) cytotoxicity depending on complement, & (D) membrane attack complex (MAC) (Fc γ RIII: Fc-gamma receptor III, Fc γ RI: Fc-gamma receptor I, AKT: protein kinase B, ERK: extracellular signal-regulated kinase, & C1q: complement component 1q)

milieu during circulation, and facilitating their accumulation at the target site through active targeting mechanisms or enhanced permeability and retention (EPR) effect are some of the most appealing characteristics of nanoparticle-based carriers (Yoo et al., 2019).

The process of functionalizing nanoparticle surfaces with ligands or antibodies that selectively identify and bind to receptors or antigens overexpressed on the surface of cancer cells allows for active targeting. By facilitating the selective uptake of nanoparticles by tumor cells, this ligand-receptor interaction increases the therapeutic index of the encapsulated medication and reduces off-target effects (Muhamad et al., 2018). It is possible to design nanoparticles so that they react to different stimuli found in the tumor microenvironment, such as pH, temperature, or enzyme activity. This allows the therapeutic delivery to be released gradually in response to particular physiological indications. Treatments for different types of cancer have advanced significantly as a result of the use of carriers based on nanoparticles in cancer therapy (Thakur et al., 2020). In contrast to free doxorubicin, liposomal preparations of chemotherapeutic drugs, such doxil (liposomal doxorubicin), have been licensed for clinical usage and offer better efficacy and decreased cardiotoxicity. Analogously, the solubility and therapeutic efficacy of medications such as paclitaxel (abraxane) have been improved by using nanoparticle albumin-bound technology, leading to better results for patients suffering from pancreatic, non-small cell lung, and breast cancer (Yu et al., 2020).

The clinical translation of nanoparticle-based carriers is still fraught with difficulties, despite their encouraging potential. It is necessary to solve issues pertaining to the large-scale manufacture, stability, repeatability, and safety of nanoparticle compositions. Furthermore, there are other obstacles to the efficient targeting and penetration of nanoparticles, including the biological complexity of the tumor microenvironment and the heterogeneity of malignancy (Lee et al., 2019). Optimizing the design and performance of nanoparticle-based carriers necessitates a multidisciplinary strategy that integrates knowledge from materials science, chemistry, biology, and medicine in order to overcome these obstacles.

Further advances in nanotechnology and our growing knowledge of tumor biology will likely shape the direction of the next wave of medication delivery devices based on nanoparticles. One example of how developments in nanoparticle design could enhance the specificity and efficacy of cancer therapies is the creation of multifunctional nanoparticles that can be utilized for simultaneous targeting, imaging, and therapy (Amreddy et al., 2018). Furthermore, there are promising opportunities for the creation of all-encompassing and individualized cancer treatment plans due to the incorporation of nanoparticles with newly developed therapeutic modalities like gene therapy and immunotherapy.

Bioengineered Proteins

The development of bioengineered proteins, which combine the ideas of targeted therapy and precision medicine, opens up new avenues for the treatment of breast cancer. These novel medicines address the shortcomings of traditional treatments by improving specificity, efficacy, and safety through the use of advanced bioengineering techniques (Cheng et al., 2018). mAbs, fusion proteins, and enzyme inhibitors are examples of bioengineered proteins that are specifically designed to target molecular pathways linked to the pathophysiology of breast cancer (**Figure 3**). These proteins can be altered via genetic engineering and protein design techniques to improve their therapeutic characteristics, such as reduced immunogenicity, improved stability in the bloodstream, and greater binding affinity for target receptors.

Bioengineered proteins allow for the exact targeting of cancer cells while maintaining healthy tissues, minimizing side effects, and improving patient QoL (Cheng et al., 2018).

One of the most effective groups of bioengineered proteins in oncology are mAbs. Targeting the HER2 receptor, which is overexpressed in 20%-30% of breast cancer cases, mAbs like trastuzumab and pertuzumab have been shown to enhance patient outcomes for HER2-positive tumors. Inhibiting the signaling pathways responsible for tumor development and proliferation, as well as occasionally directing immune responses against cancer cells, is how these antibodies function (Nielsen et al., 2013). Bioengineered proteins go far beyond mAbs and include a wide spectrum of therapies such as bispecific antibodies, which can engage two different targets at the same time, such a tumor antigen and a T-cell receptor, in order to activate and deploy the immune system against cancer cells. Furthermore, engineered growth factors and cytokines have been created to alter the tumor microenvironment, overcoming immune suppression and improving the effectiveness of immunotherapy and chemotherapy, among other treatment methods (Kintzing et al., 2016). Proteomics, bioinformatics, and structural biology developments are driving the development of bioengineered protein therapies for breast cancer because they shed light on the molecular structure of proteins and how they interact with biological targets. The logical creation of protein therapies with ideal qualities for clinical use is made possible by these technologies (Haymond et al., 2019). Furthermore, there are chances to improve the targeted and controlled release of these treatments, hence raising their therapeutic index, by integrating bioengineered proteins with drug delivery methods such nanoparticle carriers. Bioengineered proteins hold great potential for treating breast cancer, but there are still obstacles in their research and clinical application.

EFFICACY AND MECHANISMS OF ACTION

Enhancing Medication Specificity Through Innovative Delivery

Drug delivery systems have advanced significantly as a result of the quest for more effective and safer cancer treatments, with an emphasis on improving pharmaceutical specificity. Through increased selectivity to cancer cells, novel delivery systems seek to maximize the therapeutic index of anticancer medicines while reducing systemic exposure and, thus, side effects. By utilizing cutting-edge technology and innovative materials, this paradigm shift towards precision medicine has created new opportunities for the creation of targeted medicines (Yadav et al., 2021). The ability to differentiate cancer cells from healthy ones and deliver therapeutic drugs directly to the tumor site is fundamental to the idea of medication specificity. This is achieved by a variety of methods, such as stimulus-responsive systems, active targeting, and passive targeting (Senapati et al., 2018). One of the unique physiological characteristics of the tumor microenvironment that passive targeting takes advantage of is the EPR effect, which allows nanoparticles to collect preferentially in tumor tissue. Since passive targeting might not be able to achieve the best specificity on its own, active targeting approaches have been created (Cruz & Kayser, 2019).

By adding ligands or antibodies that bind selectively to receptors or antigens that are overexpressed on the surface of cancer cells, drug delivery systems can be modified for active targeting. The selective uptake of the drug delivery system by the tumor cells is facilitated by this ligand-receptor interaction, which greatly increases the concentration of the therapeutic substance at the target region. Examples are nanoparticles functionalized with targeting moieties like peptides, aptamers, or small molecules, and ADCs (Yu et al., 2022). These targeted delivery methods have demonstrated encouraging outcomes in lowering off-target toxicity, boosting chemotherapeutic efficacy, and overcoming drug resistance mechanisms. Another breakthrough in improving drug specificity is stimulus-responsive delivery devices. These systems are designed to release their therapeutic delivery in response to certain physiological or pathological cues found in the tumor microenvironment, such as pH, temperature, hypoxia, or specific enzymes. For instance, pH-sensitive nanoparticles can release chemotherapeutic medications in the acidic tumor microenvironment while preserving the neutral pH of healthy cells (Zhao et al., 2020). Similarly, overexpressed proteases in cancer cells can activate enzyme-responsive systems and cause drug release. Therapy can be tailored to the individual characteristics of the tumor thanks to the great degree of specificity and control over medication release provided by these stimulus-responsive devices (Wu et al., 2021).

The development of novel methods of delivery to improve medicine specificity has advanced, yet there are still obstacles in moving these developments from the lab to the clinic. It is necessary to solve concerns like manufacturing scalability, regulatory approval, and guaranteeing the safety and effectiveness of these innovative human delivery systems. Furthermore, obtaining consistent and predictable therapy effects is significantly hampered by the variety of malignancies and the dynamic nature of the tumor microenvironment (Terstappen et al., 2021).

Minimizing Toxicity and Adverse Effects to Enhance Patient Results

The objective of greatly improving patient results by lowering the toxicity and side effects of cancer treatment has completely changed the therapeutic landscape of oncology. Conventional cancer treatments, such radiation and chemotherapy, have a long list of unfavorable side effects that can seriously lower QoL and be crippling. This has prompted a great deal of study into methods for reducing these toxicities without sacrificing, or even improving, the effectiveness of treatment (van der Laan et al., 2021). The development of tailored medicines, which specifically target cancer cells while sparing healthy tissues, is a critical strategy for limiting damage. Targeted therapies take advantage of particular genetic variations between malignant and normal cells, in contrast to standard chemotherapy, which affects rapidly dividing cells without discrimination. This strategy is exemplified by mAbs, small molecule inhibitors, and hormone treatments, which target particular pathways or receptors important in the development and survival of cancer cells. By

concentrating on these particular targets, the likelihood and intensity of side effects are decreased by minimizing collateral harm to healthy cells (Schirrmacher, 2018). Utilizing drug delivery devices intended to improve the efficiency and specificity of drug accumulation at the tumor site is another cutting-edge tactic. Technologies such as liposomes, polymer-drug conjugates, and nanoparticle-based carriers have demonstrated potential in accomplishing this objective. Therapeutic drugs can be encapsulated in these systems to prevent premature degradation and to enable targeted distribution of the agents through either passive or active methods. Lower systemic doses are needed to ensure that higher quantities of the medicine reach the tumor, which lowers the risk of off-target damage (Large et al., 2019).

Prodrugs and stimulus-responsive delivery systems–which provide regulated drug release triggered by particular tumor microenvironment variables including acidity, hypoxia, or overexpressed enzymes–have also been developed as a result of bioengineering advancements. By focusing the drug's impact on the tumor and further lowering systemic exposure and toxicity, these systems remain dormant during circulation and become active only upon encountering the tumor-specific cues (Cong et al., 2022). Immunotherapy is another promising strategy for reducing treatment-related toxicity. By utilizing the body's immune system to fight the disease, immunotherapies–such as checkpoint inhibitors, CAR T-cell therapies, and cancer vaccines–offer a more safe and natural approach to treating cancer. Even while these therapies can have adverse effects, they are frequently different from those of conventional treatments and can be easier to handle with the right kind of supportive care (Gutierrez et al., 2020). The task of totally eradicating treatment-related toxicity in oncology continues to be difficult despite these advances. Ongoing research and individualized treatment plans are required due to patient diversity in medication metabolism and response, the complexity of cancer biology, and the possibility of resistance mechanisms (Kennedy & Salama, 2020).

With advancements in precision medicine and ongoing research into the molecular mechanisms underlying cancer and therapy response, there is optimism for significant reductions in the toxicity of cancer medicines in the future. Treatment plans that are more individualized and less hazardous may be possible if genomes, proteomics, and metabolomics are integrated. This will allow for the identification of patients who are more likely to benefit from particular medications or who are more likely to experience severe side effects (Xing & Meng, 2020).

CLINICAL APPLICATIONS AND IMPACT

Case Studies Demonstrating the Success of Novel Protein Delivery in Treatment

A new era in the treatment of several diseases, including cancer, has been brought about by the invention of creative protein delivery systems. There is now hope for better clinical results thanks to these novel strategies that have greatly increased the specificity, efficacy, and safety of protein-based therapies (Mandal et al., 2018).

Case study 1: Nanoparticle-encapsulated trastuzumab for HER2-positive breast cancer

The creation of trastuzumab encapsulated in nanoparticles for the treatment of HER2-positive breast cancer is one of the seminal achievements in innovative protein delivery. The systemic exposure and probable cardiotoxicity of traditional administration of trastuzumab, a monoclonal antibody targeting the HER2 receptor, are limitations (Mandal et al., 2018). By encasing trastuzumab in lipid nanoparticles, researchers were able to deliver the drug to tumor cells precisely, with increased penetration and retention inside the tumor microenvironment. This strategy showed greater anticancer activity in preclinical models and lessened cardiotoxic side effects; as a result, clinical trials to assess its safety and efficacy in people with breast cancer are currently being conducted (Meng et al., 2018).

Case study 2: Ligand-directed enzyme prodrug therapy for glioblastoma

One of the deadliest and most aggressive brain tumors, glioblastoma, is very hard to treat because of the blood-brain barrier and the intricate nature of the tumor microenvironment. To overcome these challenges, ligand-directed enzyme prodrug treatment is a novel technique that has showed potential. This technique involves delivering an enzyme that targets glioblastoma cells specifically by binding to receptors that are overexpressed on the tumor cells. Once inside the tumor, the enzyme transforms a non-toxic prodrug that was given separately into a strong anticancer agent by activating it at the target spot (Tibensky et al., 2022). Clinical trials are now possible because this approach significantly reduced tumor size and increased survival in preclinical models.

Case study 3: Bioengineered insulin for type 1 diabetes mellitus

Innovative protein delivery methods have transformed the management of long-term illnesses like type 1 diabetes mellitus, in addition to cancer. The development of bioengineered insulin molecules with glucose-responsive release capabilities is a revolutionary advancement (Wang et al., 2020). These insulin variations mimic the physiological release of insulin by self-regulating their activity in response to blood glucose levels. With this technique, glycemic management might be much improved, and the danger of hypoglycemia could be decreased, improving the QoL for those who have diabetes. Promising outcomes from early clinical trials demonstrate the viability and effectiveness of this strategy (Hatting et al., 2018).

Case study 4: Targeted delivery of IFN-α for hepatitis C virus infection

The use of nanoparticle carriers for the targeted delivery of interferon-alpha (IFN-α) has revolutionized the treatment of hepatitis C virus (HCV). Conventional IFN-α treatment is linked to serious adverse events and uneven patient reaction. Yet, by encasing IFN-α in liver cell-specific polyethylene glycol (PEG)-modified nanoparticles, scientists have accomplished localized antiviral action with less systemic damage. This strategy offers a more efficient and patient-

friendly option for treating HCV, as clinical trials have shown increased antiviral activity and improved tolerability (Abd Ellah et al., 2019). These case studies demonstrate the significant influence that innovative protein delivery systems have on a variety of ailments, including chronic illnesses and cancer. These cutting-edge technologies are opening the door for the upcoming generation of therapies by improving the accuracy, effectiveness, and safety of protein therapeutics. It will need multidisciplinary cooperation and ongoing research and development to turn these encouraging discoveries into widely used clinical applications, which will ultimately improve patient outcomes and care across a range of therapeutic domains.

Assessing the Safety and Efficacy of Emerging Delivery Technologies

The therapeutic landscape has been greatly expanded by the quick development of new delivery technologies, especially in the field of biomedicine. These technologies provide innovative approaches to treating complicated illnesses. These cutting-edge strategies, which include viral vectors, bioengineered delivery platforms, and nanoparticle-based systems, promise improved patient compliance, specificity, and efficacy. Nevertheless, a thorough review of these technologies' safety and effectiveness is required for their translation from the bench to the bedside, highlighting the significance of thorough preclinical and clinical assessment (Garbayo et al., 2020). The approaches used to evaluate the safety and effectiveness of new delivery methods are thoroughly examined in this article, which also highlights important discoveries, difficulties, and potential paths forward in this quickly developing subject. Any novel medicinal delivery system's development must prioritize safety assessment. These technologies' distinct advantages–such as their size, surface charge, and material composition–may also put patients at danger. For instance, carriers based on nanoparticles may cause toxicity if they build up in non-target tissues or trigger unwanted immune responses (Mansour et al., 2023). Consequently, it is crucial to conduct a comprehensive analysis of biocompatibility, immunogenicity, biodistribution, and clearance mechanisms. This entails a number of in vitro and in vivo investigations intended to detect any unfavorable consequences connected to the delivery system, such as cytotoxicity, genotoxicity, and the possibility of triggering autoimmune disease or inflammation. Assessing efficacy entails assessing the delivery system's therapeutic performance in pertinent disease models, and it is equally important (Hu et al., 2021). To attain the intended therapeutic result, this entails figuring out the best dosage, administration method, and treatment plan. The capacity of the delivery method to improve drug bioavailability, target specificity, and therapeutic index in comparison to conventional treatment modalities is usually the subject of efficacy studies. Metrics of medication concentration at the target location, target engagement, and ensuing biological responses–such as tumor regression in cancer models or enhanced biomarkers in contexts specific to a particular disease–are examples of key endpoints (Ribba et al., 2018).

The most rigorous investigation into safety and effectiveness for new delivery systems is clinical trials. Following strict regulatory guidelines, these studies aim to confirm preclinical research results in human populations. The main goals of phase I trials are safety evaluation, maximum tolerated dose calculation, and identification of any toxicities that limit dosage. Phase II and III trials assess the new delivery system's efficacy by comparing its therapeutic results to placebo or traditional therapies in larger patient groups (Fayzullin et al., 2021). The effectiveness of these trials can be greatly impacted by patient selection, particularly in the case of tailored delivery systems, based on biomarkers or illness features. Emerging delivery systems have great potential, but their clinical translation is hampered by a number of issues. These include the delivery system's stability and lifespan, the production processes' scalability, and any possible off-target impacts. Moreover, the regulatory approval procedures for these innovative treatments are frequently intricate and time-consuming, necessitating convincing evidence of benefit over risk (Souho et al., 2018).

IMPLICATIONS FOR BREAST CANCER TREATMENT

The Potential of Personalized, Surgical Alternative Therapies

A revolutionary era in healthcare has begun with the development of customized medicine, especially in the field of cancer treatment. Considerable progress in surgical alternative therapies has coincided with this paradigm shift towards tailored therapeutic approaches. Based on the concepts of precision medicine, these novel approaches seek to provide more focused, less intrusive, and highly successful treatment alternatives that are specific to the individual genetic, molecular, and clinical characteristics of each patient (Sicklick et al., 2019).

The merging of therapeutic decision-making and molecular diagnostics is at the forefront of this progress. The ability to differentiate malignancies into discrete subtypes, each with a unique prognosis and treatment response, has been made possible by the discovery of certain biomarkers and genetic alterations within tumors. With a degree of specificity and efficacy not possible with traditional treatments, this molecular profile helps in the selection of targeted medications that directly impact the pathways changed by these genetic abnormalities (Sokolenko & Imyanitov, 2018). The use of tyrosine kinase inhibitors in patients with specific mutations in the EGFR gene for non-small cell lung cancer is one illustration of the efficacy of this strategy. Using oncolytic viruses is a promising new direction in individualized surgical alternative therapy. These viruses, which have undergone genetic engineering, target and kill cancer cells only, avoiding healthy organs (Murtuza et al., 2019). Additionally, they can be engineered to express specific genes that are therapeutic, which will boost their antitumor activity and activate a strong immune response against the tumor. The approval of T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma is a major step forward in the clinical usage of oncolytic virotherapy. This shows the promise of these agents as a customized, surgical alternative therapy (Zou et al., 2020).

The introduction of chimeric antigen receptor (CAR) T-cell therapy, in particular, has greatly aided the area of immunotherapy in expanding the options for customized treatment. By genetically altering a patient's own T cells to generate CARs that recognize specific antigens on tumor cells, this technique targets and eliminates cancer cells using the immune system. The potential of CAR T-cell therapy as a groundbreaking surgical alternative treatment is highlighted by its ability to cause long-lasting remissions in a number of hematological cancers and by its tailored nature (Sur et al., 2020).

Moreover, the development of targeted drug delivery methods, like implantable drug-eluting devices and carriers based on nanoparticles, adds a new level of customization to therapy. By delivering chemotherapeutic medicines directly to the tumor site, these technologies maximize therapeutic concentrations at the site of the disease and minimize systemic exposure and related toxicities. These delivery systems' promise as customized, minimally invasive therapy alternatives is further enhanced by their capacity to be tailored based on the unique features of the tumor and its milieu. These surgically tailored alternative medicines have great potential, but there are still obstacles in the way of their general adoption (Wang et al., 2018). These include the possibility for resistance to targeted therapies, the necessity of thorough molecular profiling of malignancies, which can be resource-intensive, and the logistical and manufacturing challenges involved in customized treatments like CAR T-cell therapy. Furthermore, questions concerning these medicines' affordability and accessibility are brought up by their high cost.

Future developments in immunology, biotechnology, and genetics are expected to accelerate the creation of innovative, surgically-assisted alternative medicines. When artificial intelligence and machine learning are combined to analyze complex biological data, there is potential for the discovery of new therapeutic targets and the prediction of treatment outcomes (Chen et al., 2019). Also, there are ways to improve the effectiveness and lessen the adverse effects of these cutting-edge treatments through the continuous development of delivery technology and the investigation of combination therapies. Therefore, surgical alternative therapies that are customized for each patient are a huge step forward in the treatment of cancer because they provide highly customized, less intrusive, and more successful treatment plans.

Enhancing Quality of Life and Adherence by Minimizing Treatment Side Effects

The advancement of cancer therapy approaches has placed a growing emphasis on the effects of therapeutic interventions on patients' QoL and treatment adherence, in addition to their effectiveness. The harsh nature of traditional cancer treatments, such as radiation and chemotherapy, has historically been linked to a wide range of adverse effects, from minor and controllable to severe and incapacitating. The QoL of patients is frequently compromised by these side effects, which can also result in a decrease in treatment adherence and eventually impact therapeutic outcomes (Stahlschmidt et al., 2019). Side effects following treatment have a complex burden that includes social, psychological, and bodily aspects. Patients may physically experience organ-specific toxicities, pain, exhaustion, nausea, and other symptoms that can be upsetting and interfere with day-to-day activities. The psychological effects of the medication may exacerbate anxiety, depression, and a feeling of being in control, making the course of therapy more difficult (Ausi et al., 2021). Social isolation and financial hardship might result from the influence on employment, family life, and social activities. When combined, these components show how important it is to have treatment strategies that effectively target the disease while also prioritizing the patient's overall health. The creation and application of targeted therapies has been one of the primary methods for mitigating side effects. Targeted therapies, in contrast to conventional cytotoxic drugs, aim to obstruct particular molecular targets implicated in the development and spread of tumors. Targeted therapies can provide a more favorable safety profile by concentrating on certain targets, which are generally less common in healthy cells (Moore et al., 2018). This lowers the frequency and severity of adverse effects. mAbs and tyrosine kinase inhibitors, for instance, have completely changed the way that many malignancies, including those of the breast, lung, and colon, are treated.

Another cutting-edge strategy that has demonstrated a great deal of promise for enhancing QoL while preserving therapeutic efficacy is immunotherapy. Immunotherapies, such as checkpoint inhibitors, can achieve prolonged tumor control with a different and frequently more controllable adverse effect profile than conventional treatments by using the body's immune system to combat cancer. Furthermore, immunotherapeutic drugs' specificity for tumor antigens lowers the possibility of off-target effects, improving patient tolerance even further (Ling et al., 2022). Nanoparticle-based carriers and localized delivery devices are examples of advances in drug delivery systems that have helped minimize systemic exposure to harmful chemicals and accurately target the tumor location with therapy. By lowering the dosage necessary to produce therapeutic results, these technologies can lower the possibility of negative reactions. Moreover, these systems' controlled release characteristics can sustain ideal medication concentrations for prolonged durations, diminishing the need for frequent dosage and related adverse reactions (Yao et al., 2020).

Improving treatment adherence and controlling side effects both depend on supportive care and patient education. Patients can take an active role in their care by participating in thorough patient education programs that provide information on probable side effects, how to manage them, and how important it is to follow prescribed treatment plans. In order to manage the adverse effects of cancer treatment, enhance patients' QoL, and encourage adherence, supportive care is crucial. It include symptom management, psychosocial counseling, and dietary support (Ullgren et al., 2018). Even with these developments, it is still difficult to completely mitigate the negative consequences of cancer treatment and how they affect a person's QoL. To find new therapeutic targets, enhance medication delivery methods, and create prediction models for side effect control, ongoing research is crucial. Furthermore, customized treatment plans that consider the lifestyle, genetic, and biochemical characteristics

particular to each patient might improve side effect avoidance and therapy selection even more (Berman et al., 2020).

CHALLENGES AND OPPORTUNITIES IN PROTEIN DELIVERY RESEARCH

An emerging field in therapeutic interventions, the development and application of protein delivery systems offers innovative approaches to treat a variety of illnesses, such as cancer, metabolic disorders, and autoimmune diseases. These systems confront numerous obstacles that cut across the scientific, technological, regulatory, and commercial spheres, despite their potential to completely transform patient care (Scaletti et al., 2018). The intrinsic complexity of proteins as therapeutic agents is one of the main scientific obstacles. The body's enzymes have the power to denaturize and degrade proteins, which can seriously impair their stability and bioavailability. Protein treatments must be formulated and encapsulated using cutting-edge methods to ensure their stability during storage, transportation, and administration (Emami et al., 2018). The ability of hydrogels, biodegradable polymers, and nanoparticle carriers to prevent protein degradation and enable controlled release at the target site has been investigated. Nevertheless, there is still a long way to go until these delivery vehicles are fully protected and released with optimal efficiency (Manavitehrani et al., 2018).

Another scientific problem is the selectivity of protein distribution. The safety and effectiveness of protein therapies depend on limiting off-target effects while achieving targeted delivery to the desired tissues or cells. This calls for the creation of targeting techniques like receptor-mediated endocytosis and ligand-directed targeting that can discriminate between healthy and sick cells. Finding appropriate targets and designing delivery systems with high affinity and specificity for these targets are difficult procedures that call for a great deal of investigation and verification (Wang et al., 2018). Large-scale synthesis of protein therapies and associated delivery systems poses significant technical obstacles. Biological cells are used in biotechnological procedures to create proteins, which might result in variations in the final product's quality and quantity. It is a difficult undertaking to scale up these production procedures while maintaining the protein's activity, purity, and consistency. Furthermore, in order to preserve both the protein's and the delivery vehicle's functionality, the integration of proteins into delivery systems frequently calls for complex procedures that need to be properly optimized (Papathanasiou & Kontoravdi, 2020).

The development of protein delivery methods is significantly influenced by regulatory issues as well. These medicines must pass a rigorous approval process that includes a thorough justification of their quality, safety, and efficacy. A comprehensive grasp of the rules and regulations established by regulatory organizations is necessary for navigating the regulatory environment, as is a great deal of preclinical and clinical testing (Kretzmann et al., 2021). Protein delivery systems are generally complex and innovative, requiring further examination that can raise costs and delay development. The discovery of protein delivery systems necessitates a significant financial commitment to research, development, and clinical trials, posing equally formidable economic constraints (Jain et al., 2018). Developers face substantial risks because of the high expense of these procedures as well as the unpredictability of market and regulatory acceptance. Another crucial issue is making sure these treatments are accessible and affordable once they hit the market, particularly in low- and middle-income nations with constrained funding for healthcare (De Maria et al., 2018).

PUBLIC HEALTH PERSPECTIVE

Addressing Accessibility and Affordability in Diverse Healthcare Settings

A new era of therapeutic possibilities has been brought about by the pursuit of improvements in medical treatments, especially in the areas of precision medicine and innovative drug delivery methods. Nonetheless, many people are still unable to enjoy the benefits of these scientific and technical breakthroughs, underscoring the considerable differences in accessibility and cost among various healthcare environments (Kasztura et al., 2019). This contradiction between innovation and its fair distribution highlights a critical issue facing global health making sure that all patients, irrespective of their location or socioeconomic standing, get access to the newest and most potent therapies (Chehade et al., 2020). Many variables consider sophisticated medical treatments inaccessible, but the most significant one is their high cost of development and manufacture, which frequently results in unaffordable costs for individuals and healthcare systems. Innovative treatments, such as bioengineered proteins and tailored medications, come at a high cost since they need to undergo stringent regulatory approval procedures, sophisticated manufacturing techniques, and a great deal of research and development (Liu et al., 2019). Disparities in treatment accessibility are further exacerbated by the fact that LMICs frequently lack the infrastructure and knowledge necessary to provide these treatments. Beyond the cost of treatments, affordability also considers the larger financial impact on patients and healthcare systems. Patients in many areas are left to pay large out-of-pocket costs due to the absence of government-funded healthcare programs or comprehensive health insurance coverage (Tolba et al., 2019). This financial load may discourage people from getting therapy, cause them to stop it altogether, and ultimately have a negative impact on their health. A cycle of unmet medical requirements is created when the financial burden placed on LMIC healthcare systems prevents them from making the essential investments in infrastructure, training, and the acquisition of cutting-edge medications (Kazibwe et al., 2021).

A multidimensional strategy including stakeholders at all levels, such as governments, the pharmaceutical sector, healthcare providers, and international organizations, is required to address these difficulties. Using tiered pricing models, in which the price of medications is changed in accordance with the purchasing capacity of various nations or areas, is one possible strategy (Balderrama et al., 2020). This strategy can increase affordability while maintaining the incentive for pharmaceutical companies to innovate. The

marketing of generic and biosimilar pharmaceuticals is another strategy; these can provide affordable substitutes for pricey brand-name therapies Treatment expenses can be considerably decreased by establishing regulatory frameworks that guarantee the safety and effectiveness of these alternatives while facilitating their approval and use (Stern et al., 2021). Furthermore, through the transfer of information, technology, and resources, international partnerships and collaborations can be extremely important in helping LMICs develop their healthcare capacities.

PPPs, or public-private partnerships, are an additional strategy for raising affordability and accessibility. Through these partnerships, the capabilities of both industries may be used to further R&D, streamline production procedures, and provide cutting-edge healthcare delivery models. Furthermore, financing programs and global health initiatives that target certain illnesses or geographical areas might pool resources and coordinate efforts to remove obstacles to treatment accessibility (Hellowell, 2018). Therefore, achieving the full potential of medical treatment breakthroughs requires tackling the issues of affordability and accessibility in a variety of healthcare settings. Even though there are many obstacles along the way, the international community's combined efforts can open the door to a more equal healthcare environment (Akinyemiju et al., 2023). The gap between innovation and access can be closed so that all patients, no matter what their circumstances, can take advantage of the advances in medical science by adopting creative strategies, encouraging collaborations, and giving priority to the needs of the most vulnerable populations.

Public Health's Role in Minimizing Breast Cancer Care Barriers

In the global effort to reduce obstacles to breast cancer care, public health is essential in bridging the gap between improvements in therapy and the fair use of these resources. Geographic, social, and demographic factors continue to influence care inequalities in breast cancer despite tremendous advancements in the disease's understanding and treatment. These discrepancies highlight the essential need for comprehensive public health initiatives by impeding not only patient outcomes but also access to screening, diagnosis, and treatment (Nayyar et al., 2023). The fundamental component of public health's strategy to reduce obstacles to breast cancer treatment is the implementation of extensive screening and early detection initiatives. These programs are essential for detecting breast cancer early on, when therapies are most successful (Gakunga et al., 2019). The relevance of routine mammography screenings and public health programs that raise knowledge of breast cancer symptoms have been key factors in the rise in participation rates. In order to overcome logistical and geographic challenges, these programs must be designed to reach minority and underserved areas. They must also make use of mobile screening units, culturally appropriate materials, and multilingual resources (Adegboyega et al., 2019). Beyond examination, public health is essential in enabling access to full-spectrum care, which includes diagnosis, treatment, and support for survivorship. This entails creating integrated care pathways that facilitate patients' movement through the medical system and guarantee prompt access to specialized treatments. In order to detect service delivery gaps, establish patient navigator programs, and push for legislative reforms that improve insurance coverage for breast cancer treatments, public health agencies can work in conjunction with healthcare providers, insurance companies, and community organizations (Mériade & Rochette, 2021).

One other important obstacle that public health initiatives seek to solve is the cost of care. Patients may have significant financial hardships due to the high expense of long-term care, modern diagnostics, and treatments, especially in places with limited resources. Improving affordability requires public health policies that support the creation and use of generic drugs, bargain for reduced prescription prices, and set up financial assistance programs (Zheng et al., 2020). Minimizing financial obstacles to care also requires campaigning for health policy improvements that increase coverage and lower patient out-of-pocket costs. Public health places a high priority on the quality of care provided to patients with breast cancer, working to ensure that the most recent treatment modalities and evidence-based practices are implemented in all healthcare settings. This calls for the adoption of quality assurance and improvement initiatives within healthcare facilities, as well as ongoing professional education and training for healthcare providers (Zheng et al., 2020). In order to promote innovation and spread best practices in the treatment of breast cancer, public health organizations can assist research and collaboration between academic institutions, healthcare providers, and industry partners. Public health must address the underlying social determinants of health that underpin abnormalities in breast cancer care in addition to the inequalities themselves. The incidence and death of breast cancer can be significantly decreased by programs that target poverty, enhance access to nutritious foods, improve education, and reduce exposure to environmental risk factors). In order to promote innovation and spread best practices in the treatment of breast cancer, public health organizations can assist research and collaboration between academic institutions, healthcare providers, and industry partners. Public health must address the underlying social determinants of health that underpin abnormalities in breast cancer care in addition to the inequalities themselves. The incidence and death of breast cancer can be significantly decreased by programs that target poverty, enhance access to nutritious foods, improve education, and reduce exposure to environmental risk factors (Coughlin, 2019).

ETHICAL, REGULATORY, AND CLINICAL TRIAL CONSIDERATIONS

Ethical Considerations in Novel Treatment Approaches

The emergence of innovative therapeutic approaches such as gene therapy, precision medicine, and sophisticated biotechnologies has transformed the healthcare industry by providing hitherto unheard-of chances for treating diseases that were once untreatable. These novel strategies do, however, also provide difficult moral dilemmas that need to be carefully considered. The ethical environment surrounding

these medicines must be closely examined as we enter this new era of medicine to make sure that the highest standards of medical ethics are upheld during their development and implementation (Kalidasan & Theva Das, 2024). This investigation explores the moral issues raised by cutting-edge treatment techniques, highlighting the importance of approaching healthcare innovation with morality. The idea of patient autonomy is central to the ethical debate. Patients undergoing novel treatments are frequently faced with options that are extremely difficult and unpredictable in terms of the treatment's long-term effects, outcomes, and side effects. In this situation, ensuring informed consent necessitates reassessing the ways in which patients are informed and comprehended. Healthcare professionals need to handle these discussions delicately while giving patients clear, thorough information so they may make decisions about their care that are well-informed (Papakonstantinou & Kolettis, 2020). This difficulty is exacerbated by the speed at which science is developing, which can surpass the comprehension of novel treatments by both the patient and the professional.

Justice and equity constitute yet another crucial ethical factor. New treatment modalities can be expensive to develop and administer, which raises questions about accessibility and affordability. There is a genuine chance that these cutting-edge treatments will worsen already-existing healthcare inequities by favoring the wealthy and excluding underprivileged and marginalized groups. Policymakers, healthcare providers, and the pharmaceutical sector must work together to devise measures that guarantee fair access to innovative treatments in order to address this ethical challenge (Aguiar et al., 2019). Safety and risk concerns are part of the innovative treatments' ethical environment. Even while these therapies have a lot of potential, they frequently go into untested areas with unknown long-term hazards and unexpected outcomes. The creation and application of such treatments must be done with caution in order to uphold the ethical duty to "do no harm". To protect against possible injury, thorough preclinical and clinical testing, open reporting of data, and continuous patient outcome monitoring are crucial (Schwartz et al., 2021).

Evaluating New Therapies: The Crucial Role of Clinical Trials

Clinical trial conduct and interpretation are essential to the advancement of medical knowledge and the creation of novel medicines. Before new therapy approaches are extensively used in clinical practice, these trials are essential to assessing their safety, effectiveness, and overall usefulness. In addition to being a necessary regulatory barrier, the thorough evaluation made possible by clinical trials is a vital first step in guaranteeing that novel medicines indeed outperform current standards of care. This investigation explores the critical role that clinical trials play in assessing novel treatments, emphasizing the benefits that these trials provide to patient care, medical knowledge, and public health (Hess & Abd-Elsayed, 2019).

Clinical trials follow a set of rules that are intended to protect the welfare of participants while providing answers to certain research topics. Early-phase trials that evaluate safety and tolerability in a small number of individuals are the first step in this methodical approach. These preliminary phases are essential for figuring out the best dosage and ways to administer it while spotting any possible side effects. Later phases of the trials see a shift in focus to assessing the intervention's therapeutic efficacy in comparison to standard therapies (Radanovic et al., 2022). To ensure that the results are applicable to a wider range of patients, larger and more diverse participant groups are involved. The use of blinding, placebo controls, and randomized controlled designs, which together reduce bias and offer trustworthy information about a therapy's efficacy, highlight the methodological rigor of clinical trials. Healthcare practitioners can make well-informed decisions about the clinical and commercial viability of novel medicines with the use of statistical analysis of trial findings, which helps them select the best course of action for their patients (Tandon & Kakkis, 2021). A multidisciplinary team comprising researchers, doctors, statisticians, and ethicists must work together successfully to conduct clinical trials, and patients must actively participate in the process. Clinical trials involve significant ethical considerations, which include the necessity of informed consent, the defense of patient rights, and the fair selection of study participants. The pursuit of scientific knowledge must not eclipse the autonomy and well-being of those who contribute to this research, thanks to ethical oversight (Morain et al., 2020).

CONCLUSION AND FUTURE DIRECTIONS

Investigating new protein delivery methods for the treatment of breast cancer opens up a bright future for developing therapeutic approaches. These cutting-edge systems represent a paradigm change toward more efficient, patient-centered cancer therapy because of their ability to deliver targeted medicines, release them under controlled conditions, and stabilize them. For patients fighting breast cancer, these systems' ability to lower toxicity, increase therapy specificity, and facilitate the combination of therapeutic modalities offers a glimmer of hope. The development of treatment for breast cancer made possible by these innovative delivery methods highlights how important interdisciplinary cooperation is. To address the complex problems of cancer treatment, scientists, physicians, engineers, and pharmacologists, among others, must continue to collaborate and pool their knowledge. This cooperative mindset is crucial for the creation and improvement of protein delivery systems as well as for comprehending the biology of breast cancer, advancing diagnostic technology, and customizing patient care. Looking ahead, it is anticipated that ongoing innovation and public health campaigns will have a significant impact on breast cancer therapy. The implementation of public health plans is imperative in facilitating the availability and just allocation of cutting-edge treatments, guaranteeing that the advantages of scientific discoveries are experienced by all facets of society. Furthermore, it is essential to keep funding research and development in order to promote creativity, look into novel therapeutic targets, and improve delivery methods. The dynamic landscape of breast cancer therapy is further exemplified by the integration of digital health technology, precision medicine, and patient engagement initiatives, which

herald a new era when customized care is the rule rather than the exception. Therefore, the creation of innovative protein delivery systems is a critical step forward in the management of breast cancer and provides a route toward less invasive and more effective treatments. The path ahead, supported by innovation and public health as well as interdisciplinary collaboration, has enormous potential to change the way breast cancer care is provided. Our combined efforts will surely help to improve patient outcomes, improve QoL, and ultimately transform breast cancer therapy for future generations as we continue on this road.

Author contributions: All co-authors have involved in all stages of this study while preparing the final version. They all agree with the results and conclusions.

Funding: No funding source is reported for this study.

Acknowledgmenets: The authors would like to thank Ladoke Akintola University of Technology, Nigeria, Department of Public Health at University of Illinois at Springfield, USA, First Moscow State Medical University, Department of Epidemiology at Sechenov University, Moscow, Russia, and Department of Medicine and Surgery, University of Ibadan, Oyo State, Nigeria, for their moral support and their encouragement.

Ethical statement: The authors stated that ethics committee approval was not required for the work, therefore it was exempted. The review involves data collection using online resources involving information freely available in the public domain that does not collect or store identifiable data. All related laws, rules, and regulations required for the study's implementation have been followed. The authors further stated that the article is the original study of the authors, and it has not been published elsewhere.

Declaration of interest: No conflict of interest is declared by the authors.

Data sharing statement: Data supporting the findings and conclusions are available upon request from corresponding author.

REFERENCES

Abd Ellah, N. H., Tawfeek, H. M., John, J., & Hetta, H. F. (2019). Nanomedicine as a future therapeutic approach for hepatitis C virus. *Nanomedicine, 14*(11), 1471-1491. https://doi.org/10.2217/nnm-2018-0348

Adegboyega, A., Aroh, A., Voigts, K., & Jennifer, H. (2019). Regular mammography screening among African American (AA) women: Qualitative application of the PEN-3 framework. *Journal of Transcultural Nursing, 30*(5), 444-452. https://doi.org/10.1177/1043659618803146

Agaronnik, N. D., El-Jawahri, A., & Iezzoni, L. I. (2022). Implications of physical access barriers for breast cancer diagnosis and treatment in women with mobility disability. *Journal of Disability Policy Studies, 33*(1), 46-54. https://doi.org/10.1177/10442073211010124

Aguiar Jr, P. N., Adashek, J. J., Roitberg, F., Noia Barreto, C. M., Del Giglio, A., & Lopes Jr, G. L. (2019). In the era of cost-effectiveness analysis, affordability is a limiting factor for patients' access to innovative cancer treatments. *Value in Health Regional Issues, 20*, 47-50. https://doi.org/10.1016/j.vhri.2018.12.003

Akinyemiju, T., Chen, Q., Wilson, L. E., Previs, R. A., Joshi, A., Liang, M., Pisu, M., Ward, K. C., Berchuck, A., Schymura, M. J., & Huang, B. (2023). Healthcare access domains mediate racial disparities in ovarian cancer treatment quality in a US patient cohort: A structural equation modelling analysis. *Cancer Epidemiology, Biomarkers & Prevention, 32*(1), 74-81. https://doi.org/10.1158/1055-9965.epi-22-0650

Al-Mansoori, L., Elsinga, P., & Goda, S. K. (2021). Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy. *Biomedecine & Pharmacotherapy, 144*, Article 112260. https://doi.org/10.1016/j.biopha.2021.112260

Amreddy, N., Babu, A., Muralidharan, R., Panneerselvam, J., Srivastava, A., Ahmed, R., Mehta, M., Munshi, A., & Ramesh, R. (2018). Recent advances in nanoparticle-based cancer drug and gene delivery. In *Advances in cancer research* (pp. 115-170). Elsevier. https://doi.org/10.1016/bs.acr.2017.11.003

Ausi, Y., Santoso, P., Sunjaya, D., & Barliana, M. I. (2021). Between curing and torturing: Burden of adverse reaction in drug-resistant tuberculosis therapy. *Patient Preference and Adherence, 15*, 2597-2607. https://doi.org/10.2147/ppa.s333111

Balderrama, F., Schwartz, L. J., & Longo, C. J. (2020). When are pharmaceuticals priced fairly? An alternative risk-sharing model for pharmaceutical pricing. *Health Care Analysis: HCA: Journal of Health Philosophy and Policy, 28*(2), 121-136. https://doi.org/10.1007/s10728-020-00394-x

Bashraheel, S. S., Domling, A., & Goda, S. K. (2020). Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. *Biomedecine & Pharmacotherapy, 125*, Article 110009. https://doi.org/10.1016/j.biopha.2020.110009

Basu, P., Zhang, L., Hariprasad, R., Carvalho, A., & Barchuk, A. (2020). A pragmatic approach to tackle the rising burden of breast cancer through prevention & early detection in countries "in transition." *The Indian Journal of Medical Research, 152*(4), Article 343. https://doi.org/10.4103/ijmr.ijmr_1868_19

Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018). Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. *Journal of Controlled Release, 277*, 1-13. https://doi.org/10.1016/j.jconrel.2018.02.040

Berman, R., Davies, A., Cooksley, T., Gralla, R., Carter, L., Darlington, E., Scotté, F., & Higham, C. (2020). Supportive care: An indispensable component of modern oncology. *Clinical Oncology, 32*(11), 781-788. https://doi.org/10.1016/j.clon.2020.07.020

Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. (2022). Nanoparticle-based delivery systems for vaccines. *Vaccines, 10*(11), Article 1946. https://doi.org/10.3390/vaccines10111946

Chang, Y., Yao, S., Chen, Y., Huang, J., Wu, A., Zhang, M., Xu, F., Li, F., & Huang, Y. (2019). Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy. *Nanoscale, 11*(2), 611-621. https://doi.org/10.1039/c8nr08951e

Chehade, M. J., Yadav, L., Kopansky-Giles, D., Merolli, M., Palmer, E., Jayatilaka, A., & Slater, H. (2020). Innovations to improve access to musculoskeletal care. *Best Practice & Research Clinical Rheumatology, 34*(5), Article 101559. https://doi.org/10.1016/j.berh.2020.101559

Chen, Q., Chen, M., & Liu, Z. (2019). Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses. *Chemical Society Reviews, 48*(22), 5506-5526. https://doi.org/10.1039/c9cs00271e

Cheng, L., Yang, L., Meng, F., & Zhong, Z. (2018). Protein nanotherapeutics as an emerging modality for cancer therapy. *Advanced Healthcare Materials, 7*(20). https://doi.org/10.1002/adhm.201800685

Cong, X., Chen, J., & Xu, R. (2022). Recent progress in bio-responsive drug delivery systems for tumor therapy. *Frontiers in Bioengineering and Biotechnology, 10*. https://doi.org/10.3389/fbioe.2022.916952

Coughlin, S. S. (2019). Social determinants of breast cancer risk, stage, and survival. *Breast Cancer Research and Treatment, 177*(3), 537-548. https://doi.org/10.1007/s10549-019-05340-7

Cruz, E., & Kayser, V. (2019). Synthesis and enhanced cellular uptake in vitro of anti-HER2 multifunctional gold nanoparticles. *Cancers, 11*(6), Article 870. https://doi.org/10.3390/cancers11060870

De Maria, C., Di Pietro, L., Díaz Lantada, A., Madete, J., Makobore, P. N., Mridha, M., Ravizza, A., Torop, J., & Ahluwalia, A. (2018). Safe innovation: On medical device legislation in Europe and Africa. *Health Policy and Technology, 7*(2), 156-165. https://doi.org/10.1016/j.hlpt.2018.01.012

Delfi, M., Sartorius, R., Ashrafizadeh, M., Sharifi, E., Zhang, Y., De Berardinis, P., Zarrabi, A., Varma, R. S., Tay, F. R., Smith, B. R., & Makvandi, P. (2021). Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy. *Nano Today, 38*, Article 101119. https://doi.org/10.1016/j.nantod.2021.101119

Emami, F., Vatanara, A., Park, E., & Na, D. (2018). Drying technologies for the stability and bioavailability of biopharmaceuticals. *Pharmaceutics, 10*(3), Article 131. https://doi.org/10.3390/pharmaceutics10030131

Essa, D., Kondiah, P. P. D., Choonara, Y. E., & Pillay, V. (2020). The design of poly(lactide-co-glycolide) nanocarriers for medical applications. *Frontiers in Bioengineering and Biotechnology, 8*. https://doi.org/10.3389/fbioe.2020.00048

Fayzullin, A., Bakulina, A., Mikaelyan, K., Shekhter, A., & Guller, A. (2021). Implantable drug delivery systems and foreign body reaction: Traversing the current clinical landscape. *Bioengineering, 8*(12), Article 205. https://doi.org/10.3390/bioengineering8120205

Gakunga, R., Kinyanjui, A., Ali, Z., Ochieng', E., Gikaara, N., Maluni, F., Wata, D., Kyeng', M., Korir, A., & Subramanian, S. (2019). Identifying barriers and facilitators to breast cancer early detection and subsequent treatment engagement in Kenya: A qualitative approach. *The Oncologist, 24*(12), 1549-1556. https://doi.org/10.1634/theoncologist.2019-0257

Garbayo, E., Pascual-Gil, S., Rodríguez-Nogales, C., Saludas, L., Estella-Hermoso de Mendoza, A., & Blanco-Prieto, M. J. (2020). Nanomedicine and drug delivery systems in cancer and regenerative medicine. *Nanomedicine and Nanobiotechnology, 12*(5), Article e1637. https://doi.org/10.1002/wnan.1637

Ghione, S., Mabrouk, N., Paul, C., Bettaieb, A., & Plenchette, S. (2020). Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment. *Biochemical Pharmacology, 176*, Article 113855. https://doi.org/10.1016/j.bcp.2020.113855

Gutierrez, C., McEvoy, C., Munshi, L., Stephens, R. S., Detsky, M. E., Nates, J. L., & Pastores, S. M. (2020). Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. *Critical Care Medicine, 48*(1), 10-21. https://doi.org/10.1097/ccm.0000000000004087

Hatting, M., Tavares, C. D. J., Sharabi, K., Rines, A. K., & Puigserver, P. (2018). Insulin regulation of gluconeogenesis. *Annals of the New York Academy of Sciences, 1411*(1), 21-35. https://doi.org/10.1111/nyas.13435

Haymond, A., Davis, J. B., & Espina, V. (2019). Proteomics for cancer drug design. *Expert Review of Proteomics, 16*(8), 647-664. https://doi.org/10.1080/14789450.2019.1650025

Heer, E., Harper, A., Escandor, N., Sung, H., McCormack, V., & Fidler-Benaoudia, M. M. (2020). Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study. *The Lancet Global Health, 8*(8), e1027-e1037. https://doi.org/10.1016/s2214-109x(20)30215-1

Hellowell, M. (2018). Public private partnerships and the quality and efficiency of healthcare services. In *Public-private partnerships in health* (pp. 1-13). Springer. https://doi.org/10.1007/978-3-319-69563-1_1

Hess, A. S., & Abd-Elsayed, A. (2019). Components of clinical trials. In *Pain* (pp. 83-85). Springer. https://doi.org/10.1007/978-3-319-99124-5_21

Hu, D., Zhang, W., Tang, J., Zhou, Z., Liu, X., & Shen, Y. (2021). Improving safety of cancer immunotherapy via delivery technology. *Biomaterials, 265*, Article 120407. https://doi.org/10.1016/j.biomaterials.2020.120407

Jain, A., Singh, S. K., Arya, S. K., Kundu, S. C., & Kapoor, S. (2018). Protein nanoparticles: Promising platforms for drug delivery applications. *ACS Biomaterials Science & Engineering, 4*(12), 3939-3961. https://doi.org/10.1021/acsbiomaterials.8b01098

Kalidasan, V., & Theva Das, K. (2024). Advancing precision medicine with gene and cell therapy in Malaysia: Ethical, legal, and social implications. *Human Gene Therapy, 35*(1-2), 9-25. https://doi.org/10.1089/hum.2023.139

Kasztura, M., Richard, A., Bempong, N.-E., Loncar, D., & Flahault, A. (2019). Cost-effectiveness of precision medicine: A scoping review. *International Journal of Public Health, 64*(9), 1261-1271. https://doi.org/10.1007/s00038-019-01298-x

Kazibwe, J., Tran, P. B., & Annerstedt, K. S. (2021). The household financial burden of non-communicable diseases in low- and middle-income countries: A systematic review. *Health Research Policy and Systems, 19*(1). https://doi.org/10.1186/s12961-021-00732-y

Kennedy, L. B., & Salama, A. K. S. (2020). A review of cancer immunotherapy toxicity. *CA: A Cancer Journal for Clinicians, 70*(2), 86-104. https://doi.org/10.3322/caac.21596

Kintzing, J. R., Filsinger Interrante, M. V., & Cochran, J. R. (2016). Emerging strategies for developing next-generation protein therapeutics for cancer treatment. *Trends in Pharmacological Sciences, 37*(12), 993-1008. https://doi.org/10.1016/j.tips.2016.10.005

Kopp, W. (2019). How western diet and lifestyle drive the pandemic of obesity and civilization diseases. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 12*, 2221-2236. https://doi.org/10.2147/dmso.s216791

Kretzmann, J. A., Luther, D. C., Evans, C. W., Jeon, T., Jerome, W., Gopalakrishnan, S., Lee, Y.-W., Norret, M., Iyer, K. S., & Rotello, V. M. (2021). Regulation of proteins to the cytosol using delivery systems with engineered polymer architecture. *Journal of the American Chemical Society, 143*(12), 4758-4765. https://doi.org/10.1021/jacs.1c00258

Large, D. E., Soucy, J. R., Hebert, J., & Auguste, D. T. (2019). Advances in receptor-mediated, tumor-targeted drug delivery. *Advanced Therapeutics, 2*(1). https://doi.org/10.1002/adtp.201800091

Lee, S. W. L., Paoletti, C., Campisi, M., Osaki, T., Adriani, G., Kamm, R. D., Mattu, C., & Chiono, V. (2019). MicroRNA delivery through nanoparticles. *Journal of Controlled Release: Official Journal of the Controlled Release Society, 313*, 80-95. https://doi.org/10.1016/j.jconrel.2019.10.007

Li, N., Deng, Y., Zhou, L., Tian, T., Yang, S., Wu, Y., Zheng, Y., Zhai, Z., Hao, Q., Song, D., Zhang, D., Kang, H., & Dai, Z. (2019). Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: Results from the global burden of disease study 2017. *Journal of Hematology & Oncology, 12*(1). https://doi.org/10.1186/s13045-019-0828-0

Lima, S. M., Kehm, R. D., & Terry, M. B. (2021). Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. *eClinicalMedicine, 38*, Article 100985. https://doi.org/10.1016/j.eclinm.2021.100985

Ling, S. P., Ming, L. C., Dhaliwal, J. S., Gupta, M., Ardianto, C., Goh, K. W., Hussain, Z., & Shafqat, N. (2022). Role of immunotherapy in the treatment of cancer: A systematic review. *Cancers, 14*(21), Article 5205. https://doi.org/10.3390/cancers14215205

Liu, X., Wu, F., Ji, Y., & Yin, L. (2019). Recent advances in anti-cancer protein/peptide delivery. *Bioconjugate Chemistry, 30*(2), 305-324. https://doi.org/10.1021/acs.bioconjchem.8b00750

Low, S.-K., & Nakamura, Y. (2019). The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy. *Japanese Journal of Clinical Oncology, 49*(7), 596-603. https://doi.org/10.1093/jjco/hyz073

Manavitehrani, I., Fathi, A., Schindeler, A., & Dehghani, F. (2018). Sustained protein release from a core-shell drug carrier system comprised of mesoporous nanoparticles and an injectable hydrogel. *Macromolecular Bioscience, 18*(12). https://doi.org/10.1002/mabi.201800201

Mandal, A., Pal, D., Agrahari, V., Trinh, H. M., Joseph, M., & Mitra, A. K. (2018). Ocular delivery of proteins and peptides: Challenges and novel formulation approaches. *Advanced Drug Delivery Reviews, 126*, 67-95. https://doi.org/10.1016/j.addr.2018.01.008

Mansour, A., Romani, M., Acharya, A. B., Rahman, B., Verron, E., & Badran, Z. (2023). Drug delivery systems in regenerative medicine: An updated review. *Pharmaceutics, 15*(2), Article 695. https://doi.org/10.3390/pharmaceutics15020695

Meng, L.-X., Ren, Q., Meng, Q., Zheng, Y.-X., He, M.-L., Sun, S.-Y., Ding, Z.-J., Li, B.-C., & Wang, H.-Y. (2018). Trastuzumab modified silica nanoparticles loaded with doxorubicin for targeted and synergic therapy of breast cancer. *Artificial Cells, Nanomedicine, and Biotechnology, 46*(sup3), 556-563. https://doi.org/10.1080/21691401.2018.1501380

Mériade, L., & Rochette, C. (2021). Integrated care pathway for breast cancer: A relational and geographical approach. *Social Science & Medicine, 270*, Article 113658. https://doi.org/10.1016/j.socscimed.2020.113658

Mirza, Z., & Karim, S. (2021). Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges. *Seminars in Cancer Biology, 69*, 226-237. https://doi.org/10.1016/j.semcancer.2019.10.020

Moore, S., Leung, B., Bates, A., & Ho, C. (2018). Social isolation: Impact on treatment and survival in patients with advanced cancer. *Journal of Clinical Oncology, 36*(34_suppl), 156-156. https://doi.org/10.1200/jco.2018.36.34_suppl.156

Morain, S. R., Weinfurt, K., Bollinger, J., Geller, G., Mathews, D. J. H., & Sugarman, J. (2020). Ethics and collateral findings in pragmatic clinical trials. *The American Journal of Bioethics, 20*(1), 6-18. https://doi.org/10.1080/15265161.2020.1689031

Muhamad, N., Plengsuriyakarn, T., & Na-Bangchang, K. (2018). Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: A systematic review. *International Journal of Nanomedicine, 13*, 3921-3935. https://doi.org/10.2147/ijn.s165210

Murtuza, A., Bulbul, A., Shen, J. P., Keshavarzian, P., Woodward, B. D., Lopez-Diaz, F. J., Lippman, S. M., & Husain, H. (2019). Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. *Cancer Research, 79*(4), 689-698. https://doi.org/10.1158/0008-5472.can-18-1281

Nayyar, S., Chakole, S., Taksande, A. B., Prasad, R., Munjewar, P. K., & Wanjari, M. B. (2023). From awareness to action: A review of efforts to reduce disparities in breast cancer screening. *Cureus, 15*(6), Article e40674. https://doi.org/10.7759/cureus.40674

Nielsen, D. L., Kümler, I., Palshof, J. A. E., & Andersson, M. (2013). Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. *Breast, 22*(1), 1-12. https://doi.org/10.1016/j.breast.2012.09.008

Papakonstantinou, T., & Kolettis, T. M. (2020). Investigational therapies and patients' autonomy. *Canadian Journal of Bioethics, 3*(3), 115-117. https://doi.org/10.7202/1073786ar

Papathanasiou, M. M., & Kontoravdi, C. (2020). Engineering challenges in therapeutic protein product and process design. *Current Opinion in Chemical Engineering, 27*, 81-88. https://doi.org/10.1016/j.coche.2019.11.010

Ponce-Chazarri, L., Ponce-Blandón, J. A., Immordino, P., Giordano, A., & Morales, F. (2023). Barriers to breast cancer-screening adherence in vulnerable populations. *Cancers, 15*(3), Article 604. https://doi.org/10.3390/cancers15030604

Radanovic, I., Klarenbeek, N., Rissmann, R., Groeneveld, G. J., van Brummelen, E. M. J., Moerland, M., & Bosch, J. J. (2022). Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds. *Frontiers in Oncology, 12*. https://doi.org/10.3389/fonc.2022.954806

Rainey, L., van der Waal, D., Jervaeus, A., Wengström, Y., Evans, D. G., Donnelly, L. S., & Broeders, M. J. M. (2018). Are we ready for the challenge of implementing risk-based breast cancer screening and primary prevention? *Breast, 39*, 24-32. https://doi.org/10.1016/j.breast.2018.02.029

Ranganathan, K., Singh, P., Raghavendran, K., Wilkins, E. G., Hamill, J. B., Aliu, O., Newman, L. A., Hutton, D., & Momoh, A. O. (2021). The global macroeconomic burden of breast cancer: Implications for oncologic surgery. *Annals of Surgery, 274*(6), 1067-1072. https://doi.org/10.1097/sla.0000000000003662

Ribba, B., Boetsch, C., Nayak, T., Grimm, H. P., Charo, J., Evers, S., Klein, C., Tessier, J., Charoin, J. E., Phipps, A., Pisa, P., & Teichgräber, V. (2018). Prediction of the optimal dosing regimen using a mathematical model of tumor uptake for immunocytokine-based cancer immunotherapy. *Clinical Cancer Research, 24*(14), 3325-3333. https://doi.org/10.1158/1078-0432.ccr-17-2953

Rodríguez-Nava, C., Ortuño-Pineda, C., Illades-Aguiar, B., Flores-Alfaro, E., Leyva-Vázquez, M. A., Parra-Rojas, I., del Moral-Hernández, O., Vences-Velázquez, A., Cortés-Sarabia, K., & del Carmen Alarcón-Romero, L. (2023). Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer. *Biomedicines, 11*(6), Article 1610. https://doi.org/10.3390/biomedicines11061610

Scaletti, F., Hardie, J., Lee, Y.-W., Luther, D. C., Ray, M., & Rotello, V. M. (2018). Protein delivery into cells using inorganic nanoparticle-protein supramolecular assemblies. *Chemical Society Reviews, 47*(10), 3421-3432. https://doi.org/10.1039/c8cs00008e

Schirrmacher, V. (2018). From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment. *International Journal of Oncology, 54*(2), 407-419. https://doi.org/10.3892/ijo.2018.4661

Schwartz, D. B., Barrocas, A., Annetta, M. G., Stratton, K., McGinnis, C., Hardy, G., Wong, T., Arenas, D., Turon-Findley, M. P., Kliger, R. G., Corkins, K. G., Mirtallo, J., Amagai, T., Guenter, P., & ASPEN International Clinical Ethics Position Paper Update Workgroup. (2021). Ethical aspects of artificially administered nutrition and hydration: An ASPEN position paper. *Nutrition in Clinical Practice, 36*(2), 254-267. https://doi.org/10.1002/ncp.10633

Seidi, K., Neubauer, H. A., Moriggl, R., Jahanban-Esfahlan, R., & Javaheri, T. (2018). Tumor target amplification: Implications for nano drug delivery systems. *Journal of Controlled Release, 275*, 142-161. https://doi.org/10.1016/j.jconrel.2018.02.020

Seidu, T. A., Kutoka, P. T., Asante, D. O., Farooq, M. A., Alolga, R. N., & Bo, W. (2022). Functionalization of nanoparticulate drug delivery systems and its influence in cancer therapy. *Pharmaceutics, 14*(5), Article 1113. https://doi.org/10.3390/pharmaceutics14051113

Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018). Controlled drug delivery vehicles for cancer treatment and their performance. *Signal Transduction and Targeted Therapy, 3*(1). https://doi.org/10.1038/s41392-017-0004-3

Sicklick, J. K., Kato, S., Okamura, R., Schwaederle, M., Hahn, M. E., Williams, C. B., De, P., Krie, A., Piccioni, D. E., Miller, V. A., Ross, J. S., Benson, A., Webster, J., Stephens, P. J., Lee, J. J., Fanta, P. T., Lippman, S. M., Leyland-Jones, B., & Kurzrock, R. (2019). Molecular profiling of cancer patients enables personalized combination therapy: The I-PREDICT study. *Nature Medicine, 25*(5), 744-750. https://doi.org/10.1038/s41591-019-0407-5

Sokolenko, A. P., & Imyanitov, E. N. (2018). Molecular diagnostics in clinical oncology. *Frontiers in Molecular Biosciences, 5*. https://doi.org/10.3389/fmolb.2018.00076

Souho, T., Lamboni, L., Xiao, L., & Yang, G. (2018). Cancer hallmarks and malignancy features: Gateway for improved targeted drug delivery. *Biotechnology Advances, 36*(7), 1928-1945. https://doi.org/10.1016/j.biotechadv.2018.08.001

Stahlschmidt, R., Ferracini, A. C., de Souza, C. M., de Medeiros, L. M., Juliato, C. R. T., & Mazzola, P. G. (2019). Adherence and quality of life in women with breast cancer being treated with oral hormone therapy. *Supportive Care in Cancer, 27*(10), 3799-3804. https://doi.org/10.1007/s00520-019-04671-x

Stern, A. D., Chen, J. L., Ouellet, M., Trusheim, M. R., El-Kilani, Z., Jessup, A., & Berndt, E. R. (2021). Biosimilars and follow-on products in the United States: Adoption, prices, and users. *Health Affairs, 40*(6), 989-999. https://doi.org/10.1377/hlthaff.2020.02239

Sur, D., Havasi, A., Cainap, C., Samasca, G., Burz, C., Balacescu, O., Lupan, I., Deleanu, D., & Irimie, A. (2020). Chimeric antigen receptor T-cell therapy for colorectal cancer. *Journal of Clinical Medicine, 9*(1), Article 182. https://doi.org/10.3390/jcm9010182

Swayden, M., Chhouri, H., Anouar, Y., & Grumolato, L. (2020). Tolerant/persister cancer cells and the path to resistance to targeted therapy. *Cells, 9*(12), Article 2601. https://doi.org/10.3390/cells9122601

Tandon, P. K., & Kakkis, E. D. (2021). The multi-domain responder index: A novel analysis tool to capture a broader assessment of clinical benefit in heterogeneous complex rare diseases. *Orphanet Journal of Rare Diseases, 16*(1). https://doi.org/10.1186/s13023-021-01805-5

Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021). Strategies for delivering therapeutics across the blood-brain barrier. *Nature Reviews. Drug Discovery, 20*(5), 362-383. https://doi.org/10.1038/s41573-021-00139-y

Thakur, A., Huang, M., & Lum, L. G. (2018). Bispecific antibody based therapeutics: Strengths and challenges. *Blood Reviews, 32*(4), 339-347. https://doi.org/10.1016/j.blre.2018.02.004

Thakur, N., Thakur, S., Chatterjee, S., Das, J., & Sil, P. C. (2020). Nanoparticles as smart carriers for enhanced cancer immunotherapy. *Frontiers in Chemistry, 8*. https://doi.org/10.3389/fchem.2020.597806

Thomas, J. A., Miller, E. R., & Ward, P. R. (2022). Lifestyle interventions through participatory research: A mixed-methods systematic review of alcohol and other breast cancer behavioural risk factors. *International Journal of Environmental Research and Public Health, 19*(2), Article 980. https://doi.org/10.3390/ijerph19020980

Tibensky, M., Jakubechova, J., Altanerova, U., Pastorakova, A., Rychly, B., Baciak, L., Mravec, B., & Altaner, C. (2022). Gene-directed enzyme/prodrug therapy of rat brain tumor mediated by human mesenchymal stem cell suicide gene extracellular vesicles in vitro and in vivo. *Cancers, 14*(3), Article 735. https://doi.org/10.3390/cancers14030735

Tolba, R., Meselhy, E., & Elnagar, I. H. (2019). Global disparities in access to pain relief. In *Pain* (pp. 1185-1189). Springer. https://doi.org/10.1007/978-3-319-99124-5_252

Tong, Q., Qiu, N., Ji, J., Ye, L., & Zhai, G. (2020). Research progress in bioinspired drug delivery systems. *Expert Opinion on Drug Delivery, 17*(9), 1269-1288. https://doi.org/10.1080/17425247.2020.1783235

Tu, Y., Dong, Y., Wang, K., Shen, S., Yuan, Y., & Wang, J. (2020). Intercellular delivery of bioorthogonal chemical receptors for enhanced tumor targeting and penetration. *Biomaterials, 259*, Article 120298. https://doi.org/10.1016/j.biomaterials.2020.120298

Ullgren, H., Tsitsi, T., Papastavrou, E., & Charalambous, A. (2018). How family caregivers of cancer patients manage symptoms at home: A systematic review. International *Journal of Nursing Studies, 85*, 68-79. https://doi.org/10.1016/j.ijnurstu.2018.05.004

van der Laan, H. P., Van den Bosch, L., Schuit, E., Steenbakkers, R. J. H. M., van der Schaaf, A., & Langendijk, J. A. (2021). Impact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer. *Radiotherapy and Oncology, 160*, 47-53. https://doi.org/10.1016/j.radonc.2021.04.011

Wang, J., Wang, Z., Yu, J., Kahkoska, A. R., Buse, J. B., & Gu, Z. (2020). Glucose-responsive insulin and delivery systems: Innovation and translation. *Advanced Materials, 32*(13), Article 1902004. https://doi.org/10.1002/adma.201902004

Wang, Z., Deng, X., Ding, J., Zhou, W., Zheng, X., & Tang, G. (2018). Mechanisms of drug release in pH-sensitive micelles for tumour targeted drug delivery system: A review. *International Journal of Pharmaceutics, 535*(1-2), 253-260. https://doi.org/10.1016/j.ijpharm.2017.11.003

Wu, C., Wang, C., Zheng, Y., Zheng, Y., Liu, Z., Xu, K., & Zhong, W. (2021). Triple enzyme-regulated molecular hydrogels for carrier-free delivery of lonidamine. *Advanced Functional Materials, 31*(42). https://doi.org/10.1002/adfm.202104418

Xing, H., & Meng, L.-H. (2020). CRISPR-cas9: A powerful tool towards precision medicine in cancer treatment. *Acta Pharmacologica Sinica, 41*(5), 583-587. https://doi.org/10.1038/s41401-019-0322-9

Yadav, A., Singh, S., Sohi, H., & Dang, S. (2021). Advances in delivery of chemotherapeutic agents for cancer treatment. *AAPS PharmSciTech, 23*(1). https://doi.org/10.1208/s12249-021-02174-9

Yamaguchi, A., Anami, Y., Ha, S. Y. Y., Roeder, T. J., Xiong, W., Lee, J., Ueno, N. T., Zhang, N., An, Z., & Tsuchikama, K. (2021). Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. *Bioorganic & Medicinal Chemistry, 32*, Article 116013. https://doi.org/10.1016/j.bmc.2021.116013

Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. *Frontiers in Molecular Biosciences, 7*. https://doi.org/10.3389/fmolb.2020.00193

Yoo, J., Park, C., Yi, G., Lee, D., & Koo, H. (2019). Active targeting strategies using biological ligands for nanoparticle drug delivery systems. *Cancers, 11*(5), Article 640. https://doi.org/10.3390/cancers11050640

Yu, H., Ning, N., Meng, X., Chittasupho, C., Jiang, L., & Zhao, Y. (2022). Sequential drug delivery in targeted cancer therapy. *Pharmaceutics, 14*(3), Article 573. https://doi.org/10.3390/pharmaceutics14030573

Yu, J., Wang, Y., Zhou, S., Li, J., Wang, J., Chi, D., Wang, X., Lin, G., He, Z., & Wang, Y. (2020). Remote loading paclitaxel-doxorubicin prodrug into liposomes for cancer combination therapy. *Acta Pharmaceutica Sinica B, 10*(9), 1730-1740. https://doi.org/10.1016/j.apsb.2020.04.011

Zhang, X., Luukkonen, L. M., Eissler, C. L., Crowley, V. M., Yamashita, Y., Schafroth, M. A., Kikuchi, S., Weinstein, D. S., Symons, K. T., Nordin, B. E., Rodriguez, J. L., Wucherpfennig, T. G., Bauer, L. G., Dix, M. M., Stamos, D., Kinsella, T. M., Simon, G. M., Baltgalvis, K. A., & Cravatt, B. F. (2021). DCAF11 supports targeted protein degradation by electrophilic proteolysis-targeting chimeras. *Journal of the American Chemical Society, 143*(13), 5141-5149. https://doi.org/10.1021/jacs.1c00990

Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2020). Targeting strategies for tissue-specific drug delivery. *Cell, 181*(1), 151-167. https://doi.org/10.1016/j.cell.2020.02.001

Zheng, Z., Han, X., Zhao, J., Banegas, M. P., Tucker-Seeley, R., Rai, A., Fedewa, S. A., Song, W., Jemal, A., & Yabroff, K. R. (2020). Financial hardship, healthcare utilization, and health among U.S. cancer survivors. *American Journal of Preventive Medicine, 59*(1), 68-78. https://doi.org/10.1016/j.amepre.2020.02.016

Zou, P., Tang, R., & Luo, M. (2020). Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis. *International Immunopharmacology, 78*, Article 106050. https://doi.org/10.1016/j.intimp.2019.106050